Revenue segments as reported by the company.

Immunology

Hematologic Oncology

Aesthetics

Neuroscience

Eye Care

Women's Health

Other Key Products

All other

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative

Research and development

Acquired in-process research and development

Other operating expense

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

AbbVie

AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology, and dermatology, oncology, including blood cancers, virology, hepatitis C virus (HCV) and human immunodeficiency virus (HIV), neurological disorders, such as Parkinson's, metabolic, comprising thyroid disease and complications associated with cystic fibrosis, pain associated with endometriosis, and other serious health conditions. The company was founded on October 19, 2011 and is headquartered in North Chicago, IL.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

AbbVie surpasses Q4 earnings forecast, eyes growth amid challenges

AbbVie's strong performance in Q4 2022 exceeded expectations, driven by key products like SKYRIZI and RINVOQ. Despite challenges in revenue and HUMIRA erosion, the company is focused on innovation and growth opportunities. Strategic investments in R&D and BD aim to navigate market dynamics and drive future success.

AbbVie surpasses Q1 expectations, eyes international growth amid challenges

AbbVie's Q1 2023 performance exceeded expectations, driven by key product sales and strong international results. While facing challenges in the U.S. market and inflationary pressures, the company remains confident in its long-term growth prospects and strategic initiatives.

AbbVie surpasses Q2 expectations, eyes revenue growth opportunities

AbbVie's Q2 2023 earnings call highlighted strong financial performance, successful execution in key therapeutic areas, and a promising outlook for revenue growth. Despite challenges like biosimilar competition and market dynamics, the company remains confident in its ability to deliver value and maintain growth.

AbbVie exceeds Q3 expectations, focuses on pipeline growth strategies

AbbVie's strong Q3 performance driven by key products and growth platforms, with positive trial results.
Challenges in aesthetics sales and Medicare drug pricing program offset by long-term growth opportunities.
Confidence in pipeline assets and strategic focus on combination therapies for future growth.
Maintaining strong market positions and investing in transformative therapies for competitive advantage.

AbbVie exceeds Q4 expectations, eyes growth through strategic acquisitions

AbbVie's stellar performance in Q4 2023 showcased strong sales growth, successful pipeline advancements, and strategic acquisitions. While facing challenges such as pricing pressures and safety concerns, the company is well-positioned to capitalize on opportunities in expanding its portfolio and driving growth through innovation and strategic partnerships.

AbbVie exceeds Q1 expectations, raises full-year guidance on strong sales growth

AbbVie's Q1 performance exceeded expectations, with strong sales growth in key products. The company raised full-year guidance and remains confident in maintaining good access for its brands. Challenges in aesthetics sales and inventory management are being addressed for future growth.

AbbVie reports robust Q2 results and raises 2024 guidance

AbbVie's strong Q2 performance, raised guidance, and strategic acquisitions highlight its growth trajectory.
Despite near-term challenges, the company's focus on key growth areas positions it for long-term success.
Investments in innovation and market expansion underscore AbbVie's commitment to sustained growth.
Overall, AbbVie's performance in Q2 2024 reflects a resilient and forward-looking approach to business.

AbbVie reports strong Q3 performance, raises guidance and dividend

AbbVie's Q3 2024 performance showcased robust sales growth, increased dividend, and raised revenue guidance, reflecting financial strength and market leadership.
The company's focus on long-term sustainability through investments, acquisitions, and pipeline advancements highlights a commitment to innovation and growth.
While facing challenges in clinical trial management and market competition, AbbVie remains well-positioned to leverage opportunities in diverse therapeutic areas for future growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Humana

Marathon Petroleum

Novartis

U.S. equity markets opened mixed on Monday, with the Dow Jones industrials lagging and the tech-heavy Nasdaq adding about 1.5% in the early going.

Earnings Previews: AbbVie, Humana, Marathon Petroleum, Novartis

AbbVie's (ABBV) drugs are expected to have continued the recovering trend in sales during the fourth quarter. However, increased COVID-19 cases are likely to have hurt the pace of recovery during the quarter.

AbbVie's (ABBV) Q4 Earnings May Reflect Slower Sales Recovery

The upcoming loss of Humira exclusivity is a legitimate concern. However, robust sales of Rinvoq and Skyrizi are working to fill the gap.

'Blue Chip' You Cannot Afford To Miss, Yield 4.1%: AbbVie

Pfizer

One looks to have better growth prospects.

Better Dividend Stock: AbbVie or Pfizer?

Maybe. But neither is likely to knock Dupixent off its perch.

Can AbbVie Beat Pfizer in the Atopic Dermatitis Market?

AbbVie Inc (NYSE: ABBV) closed 2021 with a 25% gain in the stock price, and Mizuho's senior biopharmaceuticals research analyst says 2022 will be another year of outperformance for the biotech giant. Divan sees upside to $154 a share According to Vamil Divan, AbbVie is his top biotech pick, which he rates at “buy” with […] La notizia Mizuho's Vamil Divan reveals his top biotech pick era stato segnalata su Invezz.

Mizuho's Vamil Divan reveals his top biotech pick

Bank of America

Microsoft

No matter what strategy you decide is best in 2022, always remember that investing is a personal journey. Your life, and where you see yourself in 10, 20, 30 years, should be the driving force behind your investing decisions and strategies.

Value, Growth, or Momentum: What Kind of Investor are You?

Ford Motor Company

Diving into two strong stocks that also pay a dividend that investors might want to consider buying heading into earnings.

2 Stocks to Buy During Market Turbulence Before Earnings

Bristol-Myers

In this volatile market, finding solid businesses at a reasonable price is practically a luxury.

2 Dirt-Cheap Dividend Stocks to Buy and Hold Forever

Is AbbVie (ABBV) a great pick from the value investor's perspective right now? Read on to know more.

Should Value Investors Pick AbbVie (ABBV) At Present?

This stock has a lot in its favor, but there's also a big near-term risk.

2 Reasons to Buy AbbVie Stock, and 1 Reason to Sell

Recent FDA approval for Skyrizi was obtained for the treatment of adults with active psoriatic arthritis. Another recent FDA approval was for Rinvoq, which was approved for the treatment of adults and children ages 12 and older for moderate to severe atopic dermatitis.

AbbVie: Skyrizi And Rinvoq Latest FDA Approvals Bode Well For Humira Patent Loss

As we wait for the market to gain more appreciation for Abbvie, the roughly 4.15% dividend handsomely pays us for our patience.

Cramer's Investing Club Stock Profile: Drugmaker Abbvie deserves a lot more love from the market

AbbVie (ABBV) secures approval in the United States for Skyrizi to treat adult patients with active psoriatic arthritis.

AbbVie's (ABBV) Skyrizi Gets FDA Nod for Psoriatic Arthritis

IRVINE, Calif., Jan. 24, 2022 /PRNewswire/ -- Allergan Aesthetics, an AbbVie company (NYSE: ABBV) announced today it will be hosting an open casting call seeking people who would like to share their BOTOX® Cosmetic Story.

Allergan Aesthetics Announces Open Casting Call for BOTOX® Cosmetic (onabotulinumtoxinA)

CVS Health

Merck

Not only is the price right for these three healthcare stocks, but they all offer revenue growth along with an above-average dividend.

3 No-Brainer Healthcare Stocks to Buy Right Now for Less than $150

AbbVie is hoping the FDA will green light Rinvoq to treat adults with a type of back arthritis.

What This FDA News Could Mean for AbbVie's Stock

Can this high-yielder help shore up your portfolio in an unstable market?

Is AbbVie Stock a Top Pick for 2022?

NORTH CHICAGO, Ill., Jan. 21, 2022 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced the U.S. Food and Drug Administration (FDA) has approved SKYRIZI® (risankizumab-rzaa) for the treatment of adults with active psoriatic arthritis (PsA), a systemic inflammatory disease that affects the skin and joints and impacts approximately 30 percent of patients with psoriasis.1,4-7 The FDA approval is supported by data from two pivotal studies, KEEPsAKE-1 and KEEPsAKE-2, which evaluated the efficacy and safety of SKYRIZI in adults with active PsA, including those who had responded inadequately or were intolerant to biologic therapy and/or non-biologic disease-modifying antirheumatic drugs (DMARDs).2,3 Across the two Phase 3 studies, SKYRIZI met the primary endpoint of ACR20 response at week 24 compared to placebo and demonstrated significant improvements across several other manifestations of PsA, including swollen, tender and painful joints.2,3 "Patients often do not suspect a connection between their psoriasis skin symptoms and the joint pain, swelling and stiffness they may be experiencing, potentially leading to a delay in diagnosis and treatment of psoriatic arthritis," said Thomas Hudson, M.D.

U.S. FDA Approves Second Indication for SKYRIZI® (risankizumab-rzaa) to Treat Adults with Active Psoriatic Arthritis

Novavax

Valneva SE

Zogenix

Which biotech stocks are you watching today?

Top Biotech Stocks To Buy Now? 5 For Your Late January Watchlist

Andersons

Ingredion

Not all stocks are selling off to start 2022. These cheap, top Zacks Ranked stocks are doing the opposite.

3 Value Stocks Breaking out in 2022

Chevron

Leggett & Platt

When looking for great dividend stocks, one of the best places to start is with the Dividend Aristocrats. These companies have stood the test of time and economic weakness, and in the case of Leggett & Platt, AbbVie and Chevron, they all have current yields that are more than triple that of the S&P 500.

3 Dividend Aristocrats Yielding Over 4%

Sellers dominate the Street this week, but some healthcare stocks remain unaffected. Here are three to put atop your watchlist.

3 Healthcare Stocks Ignoring the Market Mayhem

Defensive investors might want to scoop up these dividend-paying pharma stocks soon.

2 Best Warren Buffett Dividend Stocks to Buy Now

Catalyst Pharmaceuticals

Horizon Pharma

Innoviva

Eli Lilly

Zoetis

As the market begins to shift from high-growth, tech-fueled start-ups, one good long-term growth option is quality pharmaceutical stocks. The post 7 of the Top-Rated Pharmaceutical Stocks for Q1 appeared first on InvestorPlace.

News for AbbVie Stock (ABBV)